Cargando…

The Non-Fibrillating N-Terminal of α-Synuclein Binds and Co-Fibrillates with Heparin

The intrinsically disordered protein α-synuclein (aSN) is, in its fibrillated state, the main component of Lewy bodies—hallmarks of Parkinson’s disease. Additional Lewy body components include glycosaminoglycans, including heparan sulfate proteoglycans. In humans, heparan sulfate has, in an age-depe...

Descripción completa

Detalles Bibliográficos
Autores principales: Skaanning, Line K., Santoro, Angelo, Skamris, Thomas, Martinsen, Jacob Hertz, D’Ursi, Anna Maria, Bucciarelli, Saskia, Vestergaard, Bente, Bugge, Katrine, Langkilde, Annette Eva, Kragelund, Birthe B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464290/
https://www.ncbi.nlm.nih.gov/pubmed/32824376
http://dx.doi.org/10.3390/biom10081192
_version_ 1783577330573115392
author Skaanning, Line K.
Santoro, Angelo
Skamris, Thomas
Martinsen, Jacob Hertz
D’Ursi, Anna Maria
Bucciarelli, Saskia
Vestergaard, Bente
Bugge, Katrine
Langkilde, Annette Eva
Kragelund, Birthe B.
author_facet Skaanning, Line K.
Santoro, Angelo
Skamris, Thomas
Martinsen, Jacob Hertz
D’Ursi, Anna Maria
Bucciarelli, Saskia
Vestergaard, Bente
Bugge, Katrine
Langkilde, Annette Eva
Kragelund, Birthe B.
author_sort Skaanning, Line K.
collection PubMed
description The intrinsically disordered protein α-synuclein (aSN) is, in its fibrillated state, the main component of Lewy bodies—hallmarks of Parkinson’s disease. Additional Lewy body components include glycosaminoglycans, including heparan sulfate proteoglycans. In humans, heparan sulfate has, in an age-dependent manner, shown increased levels of sulfation. Heparin, a highly sulfated glycosaminoglycan, is a relevant mimic for mature heparan sulfate and has been shown to influence aSN fibrillation. Here, we decompose the underlying properties of the interaction between heparin and aSN and the effect of heparin on fibrillation. Via the isolation of the first 61 residues of aSN, which lacked intrinsic fibrillation propensity, fibrillation could be induced by heparin, and access to the initial steps in fibrillation was possible. Here, structural changes with shifts from disorder via type I β-turns to β-sheets were revealed, correlating with an increase in the aSN(1–61)/heparin molar ratio. Fluorescence microscopy revealed that heparin and aSN(1–61) co-exist in the final fibrils. We conclude that heparin can induce the fibrillation of aSN(1–61), through binding to the N-terminal with an affinity that is higher in the truncated form of aSN. It does so by specifically modulating the structure of aSN via the formation of type I β-turn structures likely critical for triggering aSN fibrillation.
format Online
Article
Text
id pubmed-7464290
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74642902020-09-04 The Non-Fibrillating N-Terminal of α-Synuclein Binds and Co-Fibrillates with Heparin Skaanning, Line K. Santoro, Angelo Skamris, Thomas Martinsen, Jacob Hertz D’Ursi, Anna Maria Bucciarelli, Saskia Vestergaard, Bente Bugge, Katrine Langkilde, Annette Eva Kragelund, Birthe B. Biomolecules Article The intrinsically disordered protein α-synuclein (aSN) is, in its fibrillated state, the main component of Lewy bodies—hallmarks of Parkinson’s disease. Additional Lewy body components include glycosaminoglycans, including heparan sulfate proteoglycans. In humans, heparan sulfate has, in an age-dependent manner, shown increased levels of sulfation. Heparin, a highly sulfated glycosaminoglycan, is a relevant mimic for mature heparan sulfate and has been shown to influence aSN fibrillation. Here, we decompose the underlying properties of the interaction between heparin and aSN and the effect of heparin on fibrillation. Via the isolation of the first 61 residues of aSN, which lacked intrinsic fibrillation propensity, fibrillation could be induced by heparin, and access to the initial steps in fibrillation was possible. Here, structural changes with shifts from disorder via type I β-turns to β-sheets were revealed, correlating with an increase in the aSN(1–61)/heparin molar ratio. Fluorescence microscopy revealed that heparin and aSN(1–61) co-exist in the final fibrils. We conclude that heparin can induce the fibrillation of aSN(1–61), through binding to the N-terminal with an affinity that is higher in the truncated form of aSN. It does so by specifically modulating the structure of aSN via the formation of type I β-turn structures likely critical for triggering aSN fibrillation. MDPI 2020-08-16 /pmc/articles/PMC7464290/ /pubmed/32824376 http://dx.doi.org/10.3390/biom10081192 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Skaanning, Line K.
Santoro, Angelo
Skamris, Thomas
Martinsen, Jacob Hertz
D’Ursi, Anna Maria
Bucciarelli, Saskia
Vestergaard, Bente
Bugge, Katrine
Langkilde, Annette Eva
Kragelund, Birthe B.
The Non-Fibrillating N-Terminal of α-Synuclein Binds and Co-Fibrillates with Heparin
title The Non-Fibrillating N-Terminal of α-Synuclein Binds and Co-Fibrillates with Heparin
title_full The Non-Fibrillating N-Terminal of α-Synuclein Binds and Co-Fibrillates with Heparin
title_fullStr The Non-Fibrillating N-Terminal of α-Synuclein Binds and Co-Fibrillates with Heparin
title_full_unstemmed The Non-Fibrillating N-Terminal of α-Synuclein Binds and Co-Fibrillates with Heparin
title_short The Non-Fibrillating N-Terminal of α-Synuclein Binds and Co-Fibrillates with Heparin
title_sort non-fibrillating n-terminal of α-synuclein binds and co-fibrillates with heparin
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464290/
https://www.ncbi.nlm.nih.gov/pubmed/32824376
http://dx.doi.org/10.3390/biom10081192
work_keys_str_mv AT skaanninglinek thenonfibrillatingnterminalofasynucleinbindsandcofibrillateswithheparin
AT santoroangelo thenonfibrillatingnterminalofasynucleinbindsandcofibrillateswithheparin
AT skamristhomas thenonfibrillatingnterminalofasynucleinbindsandcofibrillateswithheparin
AT martinsenjacobhertz thenonfibrillatingnterminalofasynucleinbindsandcofibrillateswithheparin
AT dursiannamaria thenonfibrillatingnterminalofasynucleinbindsandcofibrillateswithheparin
AT bucciarellisaskia thenonfibrillatingnterminalofasynucleinbindsandcofibrillateswithheparin
AT vestergaardbente thenonfibrillatingnterminalofasynucleinbindsandcofibrillateswithheparin
AT buggekatrine thenonfibrillatingnterminalofasynucleinbindsandcofibrillateswithheparin
AT langkildeannetteeva thenonfibrillatingnterminalofasynucleinbindsandcofibrillateswithheparin
AT kragelundbirtheb thenonfibrillatingnterminalofasynucleinbindsandcofibrillateswithheparin
AT skaanninglinek nonfibrillatingnterminalofasynucleinbindsandcofibrillateswithheparin
AT santoroangelo nonfibrillatingnterminalofasynucleinbindsandcofibrillateswithheparin
AT skamristhomas nonfibrillatingnterminalofasynucleinbindsandcofibrillateswithheparin
AT martinsenjacobhertz nonfibrillatingnterminalofasynucleinbindsandcofibrillateswithheparin
AT dursiannamaria nonfibrillatingnterminalofasynucleinbindsandcofibrillateswithheparin
AT bucciarellisaskia nonfibrillatingnterminalofasynucleinbindsandcofibrillateswithheparin
AT vestergaardbente nonfibrillatingnterminalofasynucleinbindsandcofibrillateswithheparin
AT buggekatrine nonfibrillatingnterminalofasynucleinbindsandcofibrillateswithheparin
AT langkildeannetteeva nonfibrillatingnterminalofasynucleinbindsandcofibrillateswithheparin
AT kragelundbirtheb nonfibrillatingnterminalofasynucleinbindsandcofibrillateswithheparin